SMARCA4致病变体:来自实验室测试的队列中的妇科癌症病史
Brittany A Borden1, Adela Rodriguez-Hernandez2, Magan Trottier3
1Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.
Gynecologic oncology
|October 14, 2025
概括
患有SMARCA4生殖系致病性/可能致病性变体 (gPV) 的个体具有早期发病卵巢癌的高风险,特别是卵巢高血性类型 (SCCOHT) 小细胞癌. 这凸显了在基因测试和监测中对SMARCA4的需求.
科学领域:
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 在SMARCA4中生殖系致病性/可能致病性变异 (gPV) 与遗传性癌症综合征有关.
- 早期发病的卵巢癌,包括卵巢高血型小细胞癌 (SCCOHT),可能与遗传倾向有关.
研究的目的:
- 描述SMARCA4生殖系致病/可能致病变体 (gPV) 个体的癌症病史.
- 为携带SMARCA4 gPV.个体的监测和预防策略提供信息.
主要方法:
- 在127名通过多基因小组测试识别的SMARCA4 gPV个体进行了回顾性队列研究.
- 用描述性统计和累积分布函数来分析癌症诊断和诊断时的年龄.
主要成果:
- 53.5%的SMARCA4 gPV患者有癌症史.
- 卵巢高血型小细胞癌 (SCCOHT) 和未指明的卵巢癌是最常见的诊断.
- 在50岁以下的女性中,SCCOHT占癌症诊断的29.8%,所有病例都在40岁时被诊断出来.
结论:
- 应将SMARCA4纳入遗传性早期发病卵巢癌的遗传检测小组.
- 该研究为SMARCA4 gPVs患者的SCCOHT诊断提供了特定年龄的数据.
- 潜在的透性研究对于改善遗传咨询和患者管理至关重要.
更多相关视频
13:04In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
13.8K
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.6K
相关概念视频
Single Nucleotide Polymorphisms-SNPs
17.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.9K
Cancers Originate from Somatic Mutations in a Single Cell
14.6K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
